4//SEC Filing
Fromkin Andrew J. 4
Accession 0001764013-25-000034
CIK 0001764013other
Filed
Mar 10, 8:00 PM ET
Accepted
Mar 11, 4:18 PM ET
Size
7.5 KB
Accession
0001764013-25-000034
Insider Transaction Report
Form 4
Immunovant, Inc.IMVT
Fromkin Drew J
Director
Transactions
- Sale
Common Stock
2025-03-07$19.96/sh−1,384$27,625→ 91,913 total - Sale
Common Stock
2025-03-07$19.52/sh−6,616$129,144→ 93,297 total
Footnotes (3)
- [F1]The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.91 - $19.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.91 - $20.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Documents
Issuer
Immunovant, Inc.
CIK 0001764013
Entity typeother
Related Parties
1- filerCIK 0001341896
Filing Metadata
- Form type
- 4
- Filed
- Mar 10, 8:00 PM ET
- Accepted
- Mar 11, 4:18 PM ET
- Size
- 7.5 KB